On Monday, Takeda Pharmaceutical Co ADR (NYSE: TAK) was 0.22% up from the session before settling in for the closing price of $13.57. A 52-week range for TAK has been $12.57 – $15.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.56%. When this article was written, the company’s average yearly earnings per share was at -16.25%. With a float of $3.17 billion, this company’s outstanding shares have now reached $3.17 billion.
Let’s determine the extent of company efficiency that accounts for 49281 employees. In terms of profitability, gross margin is 62.49%, operating margin of 10.48%, and the pretax margin is 1.16%.
Takeda Pharmaceutical Co ADR (TAK) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Takeda Pharmaceutical Co ADR stocks. The insider ownership of Takeda Pharmaceutical Co ADR is 0.02%, while institutional ownership is 5.03%. The most recent insider transaction that took place on Aug 23 ’24, was worth 284,951. Before that another transaction happened on Jan 24 ’24, when Company’s 10% Owner sold 3,703,703 for $8.10, making the entire transaction worth $29,999,994. This insider now owns 3,755,583 shares in total.
Takeda Pharmaceutical Co ADR (TAK) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -16.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.34% during the next five years compared to -12.87% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
You can see what Takeda Pharmaceutical Co ADR (TAK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.46. Likewise, its price to free cash flow for the trailing twelve months is 11.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.31, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach 0.49 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Looking closely at Takeda Pharmaceutical Co ADR (NYSE: TAK), its last 5-days average volume was 1.32 million, which is a drop from its year-to-date volume of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 6.05%. Additionally, its Average True Range was 0.17.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 40.92%, which indicates a significant increase from 11.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.02% in the past 14 days, which was lower than the 18.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.55, while its 200-day Moving Average is $13.97. However, in the short run, Takeda Pharmaceutical Co ADR’s stock first resistance to watch stands at $13.66. Second resistance stands at $13.72. The third major resistance level sits at $13.80. If the price goes on to break the first support level at $13.52, it is likely to go to the next support level at $13.44. Should the price break the second support level, the third support level stands at $13.38.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
There are 3,164,837K outstanding shares of the company, which has a market capitalization of 43.11 billion. As of now, sales total 29,420 M while income totals 994,060 K. Its latest quarter income was 7,731 M while its last quarter net income were 609,590 K.
